Cargando…
Disease stage predicts post-diagnosis anxiety and depression only in some types of cancer
BACKGROUND: We hypothesised that patients with advanced disease or a cancer type that has a poor prognosis may be more likely to report anxiety and depressive symptoms after diagnosis; younger age and female gender may moderate these effects. METHODS: Patients (n=3850) were consecutively assessed wi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251893/ https://www.ncbi.nlm.nih.gov/pubmed/22095232 http://dx.doi.org/10.1038/bjc.2011.503 |
Sumario: | BACKGROUND: We hypothesised that patients with advanced disease or a cancer type that has a poor prognosis may be more likely to report anxiety and depressive symptoms after diagnosis; younger age and female gender may moderate these effects. METHODS: Patients (n=3850) were consecutively assessed with PSSCAN, a standardised, validated tool, at two large cancer centres between 2004 and 2009. RESULTS: Female patients reported more anxiety and depressive symptoms (P=0.003 to P<0.001) compared with men and a healthy comparison group. Older age was associated with fewer anxiety (P=0.033 to P<0.001) and fewer depressive symptoms (P<0.001), but this was not true for lung cancer. Presence of metastases was associated with more anxiety symptoms in patients with gastrointestinal (P=0.044; R(2)Δ=0.001), lung (P=0.011; R(2)Δ=0.016), and prostate (P=0.032; R(2)Δ=0.008) cancer, but this was not true for breast cancer. Furthermore, early disease stage was associated with fewer depressive symptoms among older prostate cancer patients (P=0.021; R(2)Δ=0.008). Men with early lung cancer reported fewer anxiety (P=0.020; R(2)Δ=0.013) and depressive (P=0.017; R(2)Δ=0.016) symptoms than men with advanced disease or women. CONCLUSION: As hypothesised, disease stage was directly associated with emotional distress, except for patients with breast cancer. Furthermore, age and gender moderated some of these effects. |
---|